



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/750,221	01/02/2004	Keneth K. Cyr	CRNI.111422	6658
46169 7590 01/23/2008 SHOOK, HARDY & BACON L.L.P. Intellectual Property Department 2555 GRAND BOULEVARD KANSAS CITY, MO 64108-2613			EXAMINER SEREBOFF, NEAL	
			ART UNIT 3626	PAPER NUMBER
			MAIL DATE 01/23/2008	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/750,221	Applicant(s) CYR ET AL.	
	Examiner Neal R. Sereboff	Art Unit 3626	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 08 November 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-27 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-27 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Notice to Applicant/ Response to Amendment

1. In the amendment dated 11/8/2007, claims 1, 10 and 19 have been amended. Claims 1 – 27 are pending.
2. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claim Rejections - 35 USC § 102

3. *Claims 1 – 27* are rejected under 35 U.S.C. 102(b) as being anticipated by Shalmi et al., U.S. Pre-Grant Publication Number 2002/ 0188469.
4. As per claim 1, Shalmi teaches a system for managing clinically related supply procurement according to outcomes, comprising:
 - A first interface to receive patient supply data captured from at least one clinically related site, the patient supply data comprising clinical supplies used to treat one or more patients (paragraph 53, manufacturer supply);
 - A second interface to receive clinical outcomes data that describes one or more patient outcomes that resulted from using the clinical supplies from the at least one clinically related site (paragraph 53, patient supply); and
 - An analytic engine, the analytic engine communicating with the first interface and the second interface to generate comparative clinical supply reports based at least on the clinical outcomes data (paragraph 53, needs analysis).
5. As per claim 2, Shalmi teaches the system of claim 1 as described above. Shalmi further teaches a system wherein the patient supply data comprises at least one of surgical device

information, pharmaceutical information, and consumable material information (paragraph 53, pharmaceutical information).

6. As per claim 3, Shalmi teaches the system of claim 1 as described above. Shalmi further teaches a system wherein the clinically related site comprises at least one of a hospital facility, a research facility and a government facility (paragraphs 52 or 54, hospital).

7. As per claim 4, Shalmi teaches the system of claim 1 as described above. Shalmi further teaches a system wherein the clinical outcomes data comprises at least one of patient mortality data, patient morbidity data, patient ambulatory data, patient infection data, patient prescription data, patient length of stay data, patient condition data and patient readmittance data (paragraph 53, patient prescription data).

8. As per claim 5, Shalmi teaches the system of claim 1 as described above. Shalmi further teaches a system wherein the comparative clinical supply reports comprise historical patient outcome comparisons between alternative supply selections (paragraphs 66, 67 and 72, statistical analysis and usage analysis).

9. As per claim 6, Shalmi teaches the system of claim 5 as described above. Shalmi further teaches a system wherein the historical patient outcome comparisons are based on a combination of at least two supply selections (paragraph 72 – 74, price, time and quantity).

10. As per claim 7, Shalmi teaches the system of claim 1 as described above. Shalmi further teaches a system wherein the comparative clinical supply reports comprise projected patient outcome comparisons based on alternative supply selections (paragraph 70 where usage information is kept to determine drug deployment).

11. As per claim 8, Shalmi teaches the system of claim 7 as described above. Shalmi further teaches a system wherein the projected patient outcome comparisons are based on a combination of at least two supply selections (paragraph 70, location and population or paragraph 71, price and duration or paragraph 72, usage based).

12. As per claim 9, Shalmi teaches the system of claim 1 as described above. Shalmi further teaches a system wherein the comparative clinical supply reports comprise reports on clinical outcomes data broken down according to at least one of clinical procedure type, clinical department, patient condition categories, patient demographic categories, vendor information and cost ranges (paragraphs 70 - 72, patient demographics and cost ranges).

13. As per claim 10, Shalmi teaches a method for managing clinically related supply procurement according to outcomes, comprising:

- Receiving patient supply data captured from at least one clinically related site, the patient supply data comprising clinical supplies used to treat one or more patients (paragraph 53, manufacturer supply);
- Receiving clinical outcomes data that describes one or more patient outcomes that resulted from using the clinical supplies from the at least one clinically related site (paragraph 53, patient supply); and
- Generating comparative clinical supply reports based at least on the clinical outcomes data (paragraph 53, needs analysis).

14. As per claim 11, Shalmi teaches the method of claim 10 as described above. Shalmi further teaches the method wherein the patient supply data comprises at least one of surgical

device information, pharmaceutical information, and consumable material information (paragraph 53, pharmaceutical information).

15. As per claim 12, Shalmi teaches the method of claim 10 as described above. Shalmi further teaches the method wherein the clinically related site comprises at least one of a hospital facility, a research facility and a government facility (paragraphs 52 or 54, hospital):

16. As per claim 13, Shalmi teaches the method of claim 10 as described above. Shalmi further teaches the method wherein the clinical outcomes data comprises at least one of patient mortality data, patient morbidity data, patient ambulatory data, patient infection data, patient prescription data, patient length of stay data, patient condition data and patient readmittance data (paragraph 53, patient prescription data).

17. As per claim 14, Shalmi teaches the method of claim 10 as described above. Shalmi further teaches the method wherein the comparative clinical supply reports comprise historical patient outcome comparisons between alternative supply selections (paragraphs 66, 67 and 72, statistical analysis and usage analysis).

18. As per claim 15, Shalmi teaches the method of claim 14 as described above. Shalmi further teaches the method wherein the historical patient outcome comparisons are based on a combination of at least two supply selections (paragraph 72 – 74, price, time and quantity).

19. As per claim 16, Shalmi teaches the method of claim 10 as described above. Shalmi further teaches the method wherein the comparative clinical supply reports comprise projected patient outcome comparisons based on alternative supply selections (paragraph 70 where usage information is kept to determine drug deployment).

20. As per claim 17, Shalmi teaches the method of claim 16 as described above. Shalmi further teaches the method wherein the projected patient outcome comparisons are based on a combination of at least two supply selections (paragraph 70, location and population or paragraph 71, price and duration or paragraph 72, usage based).

21. As per claim 18, Shalmi teaches the method of claim 10 as described above. Shalmi further teaches the method wherein the comparative clinical supply reports comprise reports on clinical outcomes data broken down according to at least one of clinical procedure type, clinical department, patient condition categories, patient demographic categories, vendor information and cost ranges (paragraphs 70 - 72, patient demographics and cost ranges).

22. As per claim 19, Shalmi teaches one or more computer-readable media having computer-executable instructions embodied thereon for performing a method for managing clinically related supply procurement according to outcomes, the method comprising:

- Receiving patient supply data captured from at least one clinically related site, the patient supply data comprising clinical supplies used to treat one or more patients (paragraph 53, manufacturer supply);
- Receiving clinical outcomes data that describes one or more patient outcomes that resulted from using- the clinical from the at least one clinically related site (paragraph 53, patient supply);
- Generating a comparative clinical supply report based at least on the clinical outcomes data (paragraph 53, needs analysis); and
- Storing the comparative clinical supply report in computer accessible memory (paragraph 59).

23. As per claim 20, Shalmi teaches one or more computer-readable media of claim 19 as described above. Shalmi further teaches one or more computer-readable media wherein the patient supply data comprises at least one of surgical device information, pharmaceutical information, and consumable material information (paragraph 53, pharmaceutical information).

24. As per claim 21, Shalmi teaches one or more computer-readable media of claim 19 as described above. Shalmi further teaches one or more computer-readable media wherein the clinically related site comprises at least one of a hospital facility, a research facility and a government facility (paragraphs 52 or 54, hospital).

25. As per claim 22, Shalmi teaches one or more computer-readable media of claim 19 as described above. Shalmi further teaches one or more computer-readable media wherein the clinical outcomes data comprises at least one of patient mortality data, patient morbidity data, patient ambulatory data, patient infection data, patient prescription data, patient length of stay data, patient condition data and patient readmittance data (paragraph 53, patient prescription data).

26. As per claim 23, Shalmi teaches one or more computer-readable media of claim 19 as described above. Shalmi further teaches one or more computer-readable media wherein the comparative clinical supply report comprises at least one historical patient outcome comparison between alternative supply selections (paragraphs 66, 67 and 72, statistical analysis and usage analysis).

27. As per claim 24, Shalmi teaches one or more computer-readable media of claim 23 as described above. Shalmi further teaches one or more computer-readable media wherein the at

least one historical patient outcome comparison is based on a combination of at least two supply selections (paragraph 72 – 74, price, time and quantity).

28. As per claim 25, Shalmi teaches one or more computer-readable media of claim 19 as described above. Shalmi further teaches one or more computer-readable media wherein the comparative clinical supply report comprises projected patient outcome comparisons based on alternative supply selections (paragraph 70 where usage information is kept to determine drug deployment).

29. As per claim 26, Shalmi teaches one or more computer-readable media of claim 25 as described above. Shalmi further teaches one or more computer-readable media wherein the at least one projected patient outcome comparison is based on a combination of at least two supply selections (paragraph 70, location and population or paragraph 71, price and duration or paragraph 72, usage based).

30. As per claim 27, Shalmi teaches one or more computer-readable media of claim 19 as described above. Shalmi further teaches one or more computer-readable media wherein the comparative clinical supply report comprises a report on clinical outcomes data broken down according to at least one of clinical procedure type, clinical department, patient condition categories, patient demographic categories, vendor information and cost ranges (paragraphs 70 - 72, patient demographics and cost ranges).

Response to Arguments

31. Applicant's arguments with respect to claims 1 – 27 have been considered but are moot in view of the new ground(s) of rejection.

Conclusion

Application/Control Number:
10/750,221
Art Unit: 3626

Page 9

32. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

McMenimen et al., U.S. Pre-Grant Publication Number 2002/ 0077850.


Romano, U.S. Pre-Grant Publication Number 2003/ 0132249.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Neal R. Sereboff whose telephone number is (571) 270-1373. The examiner can normally be reached on Mon thru Thur from 7:30am to 5pm, with 1st Fri off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Thomas can be reached on (571) 272-6776. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/NRS/
12/11/2007


JOSEPH THOMAS
SUPERVISORY PATENT EXAMINER